Kyverna Therapeutics (NASDAQ:KYTX) Trading Down 6.6%

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) fell 6.6% during mid-day trading on Thursday . The company traded as low as $16.40 and last traded at $16.54. 41,878 shares traded hands during trading, a decline of 89% from the average session volume of 374,995 shares. The stock had previously closed at $17.71.

Wall Street Analysts Forecast Growth

KYTX has been the subject of a number of research analyst reports. Wells Fargo & Company assumed coverage on shares of Kyverna Therapeutics in a research report on Monday, March 4th. They set an "overweight" rating and a $44.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on shares of Kyverna Therapeutics in a research note on Monday, March 4th. They set an "overweight" rating and a $39.00 target price for the company. SVB Leerink started coverage on Kyverna Therapeutics in a research note on Monday, March 4th. They set an "outperform" rating and a $48.00 price target on the stock. Leerink Partnrs restated an "outperform" rating on shares of Kyverna Therapeutics in a research note on Monday, March 4th. Finally, Morgan Stanley assumed coverage on shares of Kyverna Therapeutics in a research report on Monday, March 4th. They set an "overweight" rating and a $40.00 price target for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $42.75.

Kyverna Therapeutics Price Performance

The stock has a 50-day moving average price of $25.43.

Insider Buying and Selling

In other news, major shareholder Northpond Ventures Iii Gp, Llc bought 450,000 shares of Kyverna Therapeutics stock in a transaction that occurred on Monday, February 12th. The stock was purchased at an average cost of $22.00 per share, with a total value of $9,900,000.00. Following the completion of the transaction, the insider now directly owns 450,000 shares in the company, valued at $9,900,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.